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S leep apnea is a major risk factor for hypertension and cardiovascular diseases. 1 It is estimated that 26% of US population between 30 and 70 years have sleep apnea. 2 More importantly, the prevalence of sleep apnea in the United States has increased 28% in men and 32% in women during the past 3 decades. 2 Patients with sleep apnea exhibit increases in peripheral chemoreflex sensitivity, sympathetic nerve activity, and blood pressure. 3, 4 The sympathetic activation and hypertension occur not only during sleep but also when awake. 3 Treatments that reduce sleep apnea-induced hypertension also decrease sympathetic activity. 3 This evidence indicates that sympathetic activation contributes to sleep apnea-induced hypertension.
Exposing rats to intermittent hypoxia (IH) mimics the arterial hypoxemias that occur in patients with sleep apnea, resulting in sympathetic activation and hypertension. [5] [6] [7] IH exposure activates neurons in the paraventricular nucleus of the hypothalamus (PVN). 8 The PVN contains a large population of neurons synthesizing CRH (corticotropin-releasing hormone), indicating that IH may activate CRH-producing neurons in the PVN. Indeed, one study has reported that IH exposure increased the CRH mRNA levels in the hypothalamus. 9 CRH is well known to act in the pituitary gland to activate the hypothalamic-pituitary-adrenal axis, a key pathway in regulating the responses to stress. Interestingly, CRH-producing neurons in the PVN also project to the rostral ventrolateral medulla 10, 11 and the nucleus of the solitary tract (NTS), 12 where they may regulate sympathetic activity and blood pressure. 10, [13] [14] [15] [16] There are 2 types of CRHRs (CRH receptors): CRHR1 and CRHR2 (CRH type 1 and type 2 receptors). 17 Both CRHR1 and CRHR2 are expressed in the NTS, 18 a key nucleus in integrating the peripheral chemoreflex and baroreflex inputs and regulating the sympathetic outflow. Neurons in the NTS have been shown to contribute to sustained increase of blood pressure during IH exposure, 19, 20 but the role of NTS CRH receptors in IH-induced hypertension remains unknown.
The present study tested the hypothesis that CRH receptors in the NTS contribute to IH-induced hypertension. We first used in situ hybridization to study how IH exposure influences the anatomic distribution of CRHRs in the NTS. We then conducted calcium imaging on brain slices to study how CRH regulates intracellular calcium dynamics of NTS neurons and how IH exposure affects the CRH-induced changes of intracellular calcium levels in NTS neurons. Based on the findings from the in situ hybridization and calcium imaging experiments, we chronically infused agonist and antagonist for CRHR2 into the fourth ventricle of rats and studied the cardiovascular responses to IH exposure.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. For detailed methods, please see the online-only Data Supplement.
Animals
Male Sprague-Dawley rats (8 weeks old, 200-250 g), purchased from Charles River Laboratories (Wilmington, MA), were individually housed in a temperature-controlled room on a 12 hours light:12 hours dark cycle (on at 0700, off at 1900) and given ad libitum access to food and water. Rats that did not recover from surgeries or lost telemetry signals were excluded from the study. The study used only male rats because female rats (similar age compared with the male rats used in the present study) are protected from the hypertension induced by IH exposure. 21 All procedures were approved by the University of North Texas Health Science Center Institutional Animal Care and Use Committee.
Intermittent Hypoxia
The IH protocol has been previously described. 20 Briefly, individually housed rats were placed in custom-built plexiglass chambers and were exposed to cycles of hypoxia. Each cycle consisted of 3 minutes of 10% O 2 followed by 3 minutes of 21% O 2 . Rats were exposed to IH for 80 cycles (8 hours, 0800-1600) daily for 7 consecutive days. Rats were euthanized the day after the 7 days IH exposure.
Data Analysis
Group Assignment, data collection, and data analysis were conducted by the same people. Data were analyzed using RStudio 22 and were visualized using the ggplot2 package. Figures were assembled using the magick package. In situ hybridization results were analyzed using 2-way mixed model ANOVA with receptor type (CRHR1 versus CRHR2) or treatment (control [CON] versus IH) as a between-subject factor and location (distance caudal to bregma) as a within-subject factor. Calcium imaging results were analyzed using 1-way ANOVA with post hoc Tukey honest significance test; the results were also analyzed using χ 2 test to determine whether different treatments affected the percentage of cells responded. The 24-hour average mean arterial pressure (MAP) and heart rate (HR) values were calculated to represent daily levels for each treatment group; the results were then analyzed using 2-way mixed model ANOVA with treatment as a between-subject factor and day as a within-subject factor. Post hoc comparisons for 2-way mixed model ANOVA were conducted using the least squares mean method, with P values adjusted using Tukey method, and degrees of freedom calculated using Satterthwaite method; Post hoc comparisons were conducted using the lsmeans package. Significance level was set at P<0.05.
Results

NTS Had Higher mRNA Levels of CRHR2 Than CRHR1
Using RNAscope in situ hybridization, we detected both CRHR1 and CRHR2 mRNAs in the caudal NTS (13.68-14.76 mm caudal to bregma; Figure 1 (P<0.001; F [9, 27] =13. 29) , and the interaction between the factors receptor type and location (P<0.001; F [9, 30] =16.57). Post hoc multiple comparisons of the mRNA levels between the factor receptor type within the factor location revealed that CRHR2 mRNA levels were significantly higher than CRHR1 mRNA levels in the segment of NTS that is 13.92 to 14.28 mm caudal to bregma (P≤0.0007 in all 4 locations, t values ranged from 3.39 to 10.35; Figure 1E and 1F). Figure 1F ).
IH Decreased CRHR2 but not CRHR1 mRNA Levels in the NTS
CRH Induced Calcium Influx in NTS Neurons
Perfusion of 100 nmol/L CRH elicited an increase of intracellular calcium level in NTS neurons ( Figure 2A ). This response was reproduced in the presence of TTX (tetrodotoxin; Figure 2B 67) , indicating that the CRH-induced calcium response was independent of action potentials. The CRHinduced increase of intracellular calcium level was abolished by depletion of extracellular calcium (0 out of 79 cells responded from 9 brain slices; Figure 2C ) or by the L-type calcium channel blocker Nifedipine (0 out of 49 cells responded from 7 brain slices; Figure 2D ), indicating that CRH induced calcium influx.
CRH Induced Calcium Influx in NTS Neurons by Activating CRHR2
Coperfusion of CRH and CRHR1 antagonist NBI-35 965 induced calcium influx (13 out of 79 cells responded from 7 brain slices; Figure 3A) , with similar magnitude compared with that induced by CRH alone (P=1; Figure 3E ). Coperfusion of CRH and CRHR2 antagonist K41498 induced calcium influx (11 out of 124 cells responded from 8 brain slices; Figure 3B ), but the magnitude of the response was significantly smaller than that induced by CRH alone (P=0.003; Figure 3E ). CRHR1 agonist Stressin 1 did not affect intracellular calcium level (0 out of 121 cells responded from 14 brain slices; Figure 3C ), but CRHR2 agonist Urocortin II induced calcium influx (9 out of 69 cells responded from 7 brain slices; Figure 3D ) similar to that induced by CRH (P=0.58; Figure 3E ).
IH Attenuated the CRH-Induced Calcium Influx in NTS Neurons
To study whether IH-induced downregulation of CRHR2 mRNA leads to reduction of the CRH-induced calcium influx, we compared the CRH-induced calcium influx in IH-exposed rats to that in control rats. The magnitude of the CRH-induced calcium influx in IH-exposed rats was 44.4% less compared with that in control rats (P=0.001; Figure 4A Intra-fourth ventricle infusion of K41498 (dose: 688 pmol/h) did not affect the basal MAP but significantly attenuated IH-induced increase of MAP (aCSF, n=7; K41498, n=6; Figure 5A ). Two-way mixed model ANOVA analysis revealed significant effects of the factor day (P<0.0001, F [11, 121] =3.16) and the interaction between the factors day and treatment (aCSF or K41498; P=0.01; F [11, 121]=2.36). Post hoc multiple comparisons of the MAP between the factor day within the factor treatment revealed that, in rats infused with aCSF, the MAP was significantly increased from day 6 to day 12 (day 6, P=0.005, t [121]=4.07; day 7-12, P≤0.0001, t (121) ranged from 5.20 to 7.12; Figure 5A ) compared with day 5 (the day before IH started), suggesting that IH significantly increased MAP in rats infused with aCSF. Post hoc multiple comparisons of the MAP between the factor treatment within the factor day revealed that the MAP was significantly decreased in rats infused with K41498 compared with rats infused with aCSF from day 7 to day 9 (day 7, P=0. 03 Figure 5A ). The MAP was not different between rats infused with K41498 and rats infused with aCSF from day 10 to day 12 (P values ranged from 0.07 to 0.1; t values ranged from 1.67 to 1.86). We also found that the average MAP during the 7-day IH exposure period was significantly decreased by 40% in rats infused with K41498 compared with rats infused with aCSF (aCSF, 5±1 mm Hg versus K41498, 3±1 mm Hg; P=0.03, t [11] =2.47). These results combined suggest that K41498 significantly attenuated IH-induced hypertension during the initiation phase. A lower dose of K41498 (100 pmol/h) was initially tested and did not affect the MAP at basal condition (average Delta MAP of day 2-5; aCSF, 1±1 mm Hg versus low dose K41498, 1±2 mm Hg; P=0.90) or during IH exposure (average Delta MAP of day 6-12; aCSF, 5±1 mm Hg versus low dose K41498, 5±1 mm Hg; P=0.92).
Intra-fourth ventricle infusion of K41498 (dose: 688 pmol/h) did not affect the basal HR but significantly attenuated IH-induced increase of HR (aCSF, n=7; K41498, n=6; Figure 5B ). Two-way mixed model ANOVA analysis revealed significant effects of the factor day (P<0.0001; F [11, 121] Figure 5B ) compared with day 5 (the day before IH started), suggesting that IH significantly increased HR in rats infused with aCSF. Post hoc multiple comparisons of the HR between the factor treatment within the factor day revealed that the HR was significantly decreased in rats infused with K41498 compared with rats infused with aCSF on day 8 to 9 and day 11 to 12 (day 8 Figure 5B ).
Intra-Fourth Ventricle Infusion of CRHR2 Agonist Exacerbated IH-Induced Hypertension
Rats were randomly assigned to vehicle treatment group (n=5) or Urocortin II treatment group (n=5). At the beginning of the study, 2 treatment groups had no difference in baseline MAP Intra-fourth ventricle infusion of Urocortin II (dose: 100 pmol/h) significantly increased the basal MAP and the MAP during IH exposure (vehicle, n=5; Urocortin II, n=5; Figure 5C ). Two-way mixed model ANOVA analysis revealed significant effects of the factor day (P<0.0001; F [11, 88] Figure 5C ) compared with day 5 (the day before IH started), suggesting that IH significantly increased MAP in rats infused with vehicle (10% dimethyl sulfoxide in aCSF). Post hoc multiple comparisons of the MAP between the factor treatment within the factor day revealed that the MAP was significantly increased in rats infused with Urocortin II compared with rats infused with vehicle from day 3 to day 12 (P<0.001 in all comparisons, t [20.6] ranges from 3.90 to 5.38; Figure 5C ), suggesting that Urocortin II significantly increased baseline blood pressure and exacerbated IH-induced hypertension.
Intra-fourth ventricle infusion of Urocortin II did not affect the HR at baseline condition or during IH exposure (vehicle, n=5; Urocortin II, n=5). Two-way mixed model ANOVA analysis revealed no effects of the factor day (P=0.46, F [11, 88] 
Discussion
CRH has been well documented to regulate blood pressure by acting in the central nervous system. Several studies have shown that intracerebroventricular injection of CRH increased blood pressure. [23] [24] [25] [26] [27] [28] Intracerebroventricular injection of CRH elevated blood pressure in hypophysectomized rats and dexamethasone-treated rats but not in ganglionically blocked rats. 24 Intracerebroventricular injection of CRH increased sympathetic nerve activity and plasma catecholamine levels in rats and rabbits. 26, 29, 30 These studies suggest that sympathetic activation mediates the CRH-induced pressor response.
We found that the NTS, a key nucleus regulating sympathetic function, expresses high level of CRHR2 mRNA and relatively lower level of CRHR1 mRNA. This finding is consistent with a previous study by Van Pett et al. 18 The study by Van Pett et al 18 also showed that among all the brain stem regions that regulate sympathetic outflow to the cardiovascular system, CRHR2 is highly expressed in the NTS. Therefore, the effects of intra-fourth ventricle infusion of CRHR2 agonist/antagonist on IH-induced hypertension can be mainly attributed to the CRHR2 located in the NTS. The current study also found that IH exposure attenuated the mRNA level of CRHR2 in the NTS but did not affect that of CRHR1, indicating that IH exposure downregulates CRHR2 signaling pathways in the NTS.
The CRHR2 signaling pathways in the NTS have not been well established. The current study is the first to show that CRH increases intracellular calcium levels in NTS neurons by activating CRHR2 rather than CRHR1. This response was also observed in the presence of TTX, suggesting that the CRHinduced calcium response was independent of action potentials. The CRH-induced calcium response was abolished by depleting extracellular calcium or by perfusion of Nifedipine, indicating that CRH induces calcium influx from the extracellular region. The effect of the CRH-induced calcium influx on neuronal activity remains unknown. Increasing intracellular calcium levels may activate calmodulin-dependent protein kinases, which can increase the single-channel conductance of glutamate receptors 31 and facilitate glutamate-mediated neuronal excitation. Increasing intracellular calcium levels may activate calcium-gated potassium channels, 32 resulting in inhibition of neuronal activity. Increasing intracellular calcium levels may regulate gene transcription, 33 which can lead to either facilitation or inhibition of neuronal activity.
We then asked the question whether inhibition of CRHR2 mRNA and CRHR2-mediated calcium influx contributes to or serves as an adaptive response to IH-induced hypertension. The finding that intra-fourth ventricle infusion of CRHR2 antagonist attenuated IH-induced increase of MAP indicates that activation of CRHR2 contributes to IH-induced hypertension. Therefore, downregulation of CRHR2 signaling pathway is likely an adaptive response to protect against IH-induced hypertension. Activating CRHR2 in the NTS compromises this adaptive defensive mechanism, which explains why intrafourth ventricle infusion of CRHR2 agonist Urocortin II exacerbated IH-induced hypertension.
The current study observed that IH modestly increased MAP by ≈5 mm Hg, which is consistent with many previous studies. [5] [6] [7] Intra-fourth ventricle infusion of CRHR2 antagonist attenuated IH-induced increase of MAP by 40%, indicating CRHR2 plays an important role in IH-induced hypertension. During the 7-day IH exposure, CRHR2 antagonist only attenuated the increase of MAP from day 2 to 4 but did not significantly affect the MAP from day 5 to 7, suggesting that CRHR2 mainly contributes to the initiation phase of IH-induced hypertension.
The cellular and molecular mechanisms of how downregulation of CRHR2 signaling pathways protects against IH-induced hypertension remain unestablished. It is well established that IH-induced hypertension is dependent on chemoreceptor inputs because carotid body denervation abolished IH-induced sympathetic activation and hypertension. 5, 34, 35 Increased chemoreceptor afferent activity can lead to sustained activation and increased reactivity of neurons in the NTS. Indeed, in vitro studies have reported that IH exposure not only increased the basal discharge rate of NTS neurons but also augmented the response of NTS neurons evoked by acute repetitive stimulation of the solitary tract at a rate similar to hypoxic sensory neuron discharge in vivo 36 ; IH exposure also facilitated the response of NTS neurons to excitatory amino acid α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. 37 Knocking down tyrosine hydroxylase or the transcription factor ΔFosB from NTS neurons attenuated IH-induced hypertension, 19, 20 suggesting activation of NTS neurons contributes to IH-induced hypertension. Based on these studies, we propose that the decrease of CRHR2-mediated calcium influx observed in the present study may serve as an adaptive response to prevent overexcitation of NTS neurons caused by increased chemoreceptor afferent activity during IH exposure. Intra-fourth ventricle infusion of CRHR2 antagonist possibly strengthens this adaptive defensive mechanism by further reducing the excitability of NTS neurons, resulting in attenuation of IH-induced hypertension.
The current study reveals a pressor effect of CRHR2 in the NTS, but it cannot determine whether CRHR2 in the NTS regulates chemoreflex or baroreflex. Contrary to the present study, some previous studies indicate that CRH in the NTS decreases blood pressure by activating baroreflex. Microinjection of CRH or CRHR agonists into the NTS rapidly (within 10 seconds) decreased basal levels of sympathetic nerve activity and blood pressure 10, [14] [15] [16] ; the depressor response was attenuated by intra-NTS microinjection of CRHR2 antagonist. 15 It must be noted that the injection sites of the previous microinjections studies were localized in the medial NTS, [14] [15] [16] where baroreflex afferents are mainly located, 38 whereas the fourth ventricle infusion conducted in the current study affects a broader area of the NTS. Additionally, the microinjection studies were conducted in anesthetized rats, whereas the current study was conducted in conscious rats. These differences in experimental conditions may explain the different effects of CRHR2 on regulating blood pressure in different studies.
The NTS receives CRH inputs from the PVN and the central nucleus of the amygdala. 12, 39 Which specific CRH pathway(s) is/are involved in IH-induced hypertension remains undetermined. To date, there are more studies indicating the involvement of PVN than those indicating the involvement of central nucleus of the amygdala. A major role of central nucleus of the amygdala is to regulate responses to psychological stress, but IH exposure did not affect the stressinduced neuronal activation (cFos) in the amygdala. 40 In comparison, after IH exposure, the transcription factor ΔFosB was elevated in the PVN to mediate neuronal activation 8 ; unfortunately, the central nucleus of the amygdala was not examined in that study. Functional studies have demonstrated that PVN neurons contribute to IH-induced sympathetic activation and hypertension. 6, 41 Based on these studies, it is likely that the descending CRH pathway from the PVN to the NTS plays an important role in IH-induced hypertension.
Perspectives
The present study provides the first evidence that CRHR2 in the NTS plays an important role in IH-induced hypertension. Downregulation of CRHR2 and CRHR2-mediated calcium influx in the NTS during exposure to IH may serve as an adaptive response to protect NTS neurons from being overactivated by increased chemoreceptor afferent activity. Consequently, this adaptive mechanism may limit IH-induced hypertension.
